Bullous Pemphigoid Market to Exhibit Moderate Growth During the Forecast Period (2022-32) | Key Players – Alkahest, Immune Pharma, Akari Therapeutics, TWi Biotechnology, Eli Lilly, Regeneron, Nihon

Bullous Pemphigoid Market to Exhibit Moderate Growth During the Forecast Period (2022-32) | Key Players - Alkahest, Immune Pharma, Akari Therapeutics, TWi Biotechnology, Eli Lilly, Regeneron, Nihon
Delveinsight Business Research LLP
The therapeutic options for Bullous pemphigoid have been transformed significantly in the past decade. Currently, the market size of Bullous Pemphigoid is dominated by corticosteroids (either in pill or topical form), antibiotics, and other anti-inflammatory drugs, which are used as the first line of treatment.

As per DelveInsight, the Bullous Pemphigoid therapeutics market is expected to evolve significantly in the coming years owing to the launch of new therapies and active research and development (R&D) activities by pharma giants in the therapeutics market. Additionally, the escalating geriatric population and increased life expectancy over the globe intensifying the incidence of disease will also contribute to market growth. 

DelveInsight’s “Bullous Pemphigoid Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Bullous Pemphigoid market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Bullous Pemphigoid market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Bullous Pemphigoid: An Overview

Bullous Pemphigoid (BP) is a chronic, inflammatory, subepidermal, blistering disease. It usually presents with generalized crops of tense, pruritic cutaneous blisters and mostly affects old age people. In up to 20% of cases, BP may initially exhibit a non-bullous phase categorized by eczematous, excoriated, urticaria-like or nodular lesions, which may last weeks, months, or irregularly remain the sole clinical manifestation.

If untreated, it can persist for months or years, with periods of spontaneous remissions and exacerbations, and it could be fatal, particularly in patients who are undiagnosed. The blisters develop on areas of skin that often flex, such as the lower abdomen, upper thighs, or armpits.

Bullous Pemphigoid Market Key Facts

  • As per Brick et al., the incidence of Bullous Pemphigoid in the US is comparable to that found in Europe. However, the mortality rate of Bullous Pemphigoid is lower in the US than in Europe.

  • Based on various data analyses, the prevalence of Bullous Pemphigoid has been estimated as 259 per million population in Germany (Hubner et al., 2014). 

Bullous Pemphigoid Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Bullous Pemphigoid market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Bullous Pemphigoid market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Bullous Pemphigoid Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Bullous Pemphigoid Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bullous Pemphigoid market or expected to get launched during the study period. The analysis covers the Bullous Pemphigoid market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Bullous Pemphigoid Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Bullous Pemphigoid Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/bullous-pemphigoid-market

The Leading Companies in the Bullous Pemphigoid Market Include:

  • Immune Pharmaceuticals

  • Akari Therapeutics

  • Eli Lilly and Company

  • Regeneron Pharmaceuticals

  • Nihon Pharmaceuticals

  • Sanofi

  • AstraZeneca

  • Alkahest

  • Amgen

  • TWi Biotechnology

And many others. 

Bullous Pemphigoid Therapies covered in the report include:

  • Bertilimumab

  • Coversin

  • Ixekizumab

  • Dupilumab

  • AC-203

  • Kenketsu GLOVENIN-I (NPB-01)

And many others.

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @ 


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Bullous Pemphigoid Competitive Intelligence Analysis

4. Bullous Pemphigoid Market Overview at a Glance

5. Bullous Pemphigoid Disease Background and Overview

6. Bullous Pemphigoid Patient Journey

7. Bullous Pemphigoid Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Bullous Pemphigoid Treatment Algorithm, Current Treatment, and Medical Practices

9. Bullous Pemphigoid Unmet Needs

10. Key Endpoints of Bullous Pemphigoid Treatment

11. Bullous Pemphigoid Marketed Products

12. Bullous Pemphigoid Emerging Drugs and Latest Therapeutic Advances

13. Bullous Pemphigoid Seven Major Market Analysis

14. Attribute Analysis

15. Bullous Pemphigoid Market Outlook (In US, EU5, and Japan)

16. Bullous Pemphigoid Access and Reimbursement Overview

17. KOL Views on the Bullous Pemphigoid Market

18. Bullous Pemphigoid Market Drivers

19. Bullous Pemphigoid Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 


Other Trending Healthcare Reports By DelveInsight

Bullous Pemphigoid Pipeline Insights

“Bullous Pemphigoid – Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Bullous Pemphigoid pipeline landscape. It analyzes the pipeline drug profiles, including clinical and nonclinical stage products. Moreover, it also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/